Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. filed its annual report detailing progress on its base editing platform, clinical pipeline, and major partnerships. The company is advancing multiple programs, including risto-cel for sickle cell disease with a planned biologics license application as early as year-end 2026, BEAM-302 for alpha-1 antitrypsin deficiency under an FDA-aligned accelerated approval pathway, and BEAM-301 and BEAM-304 for rare liver-mediated genetic diseases.
Beam highlights a fully integrated model combining proprietary base editors, lipid nanoparticle and ex vivo delivery, and internal cGMP manufacturing. The report also describes significant collaboration activity, including a liver-targeted candidate licensed to Pfizer, a $200.0 million upfront plus $25.0 million in milestones from Eli Lilly tied to Verve-related rights, and $255.1 million in cash proceeds from the sale of its Orbital Therapeutics stake.
Beam Therapeutics entered a senior secured term loan facility of up to $500 million with Sixth Street, providing long-term, largely non-dilutive capital to support risto-cel and other programs. The credit facility includes $100 million funded at closing and additional potential tranches tied to FDA and revenue milestones, matures in 2033, and bears interest at 3‑month SOFR plus 6.50% with a 1.00% floor.
The company reported strong fourth-quarter 2025 results, driven by license and collaboration revenue of $114.1 million and a $255.1 million gain on sale of an equity method investment, resulting in net income of $244.3 million or $2.37 per basic share. Cash, cash equivalents and marketable securities were $1.25 billion as of December 31, 2025, and, together with at least $200 million expected from the facility, are projected to fund operations into mid‑2029.
Beam also expanded its liver-targeted franchise with BEAM‑304 for phenylketonuria, aiming for an IND filing in 2026, advanced BEAM‑302 in alpha‑1 antitrypsin deficiency under an FDA-aligned accelerated approval plan, and reiterated plans to submit a BLA for risto‑cel in sickle cell disease as early as year-end 2026.
Beam Therapeutics Inc. entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to protect its access to certain licensed patents if the existing Kobe-Bio Palette License ends. If that license terminates under specified conditions, Kobe will grant Beam an exclusive license to practice the same patents and scope it currently accesses through Bio Palette. After the termination becomes effective, Beam will make payments to Kobe in amounts that would otherwise become payable to Bio Palette under the existing Bio Palette-Beam License. This structure is designed to ensure continuity of Beam’s patent rights around its licensed technology.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in BEAM Therapeutics Inc. common stock. As of 12/31/2025, it beneficially owned 5,228,529 shares, representing 5.2% of the outstanding common stock.
State Street reports shared voting power over 4,949,918 shares and shared dispositive power over 5,228,529 shares, with no sole voting or dispositive power. The filing is certified as being made in the ordinary course of business and not for the purpose of influencing control of BEAM Therapeutics.
Beam Therapeutics Inc. reported that Carole Ho has submitted her resignation from the company’s Board of Directors. Her resignation is effective February 27, 2026, giving the company a short transition period to adjust its board composition.
The company states that Dr. Ho’s decision to resign did not result from any disagreement regarding Beam’s operations, policies, or practices. This indicates a voluntary board change rather than a response to a dispute or governance conflict.
Beam Therapeutics Inc. received an amended Schedule 13G from Farallon-managed investment funds and related entities reporting a large passive stake in its common stock. As of the reporting date, the Farallon Funds together hold 10,096,711 Shares and 1,404,988 Common Stock Purchase Warrants.
Each Warrant is exercisable for one Share but is subject to a 9.99% Beneficial Ownership Limitation, which currently allows exercise for only 45,145 Shares; the remaining 1,359,843 Warrants are treated as not exercisable within 60 days. Multiple Farallon entities and individual managers, including Joshua J. Dapice and others, may be deemed beneficial owners, with several reporting 10,141,856 Shares, or 9.99% of the class.
The amendment also updates governance of the Farallon General Partner: effective January 1, 2026, Avner A. Husen became a member/manager of the relevant general partners and may be deemed a beneficial owner, while effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles and may no longer be deemed beneficial owners. The filing states the securities are not held to change or influence control of Beam.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G showing significant ownership in Beam Therapeutics Inc.12/31/202512,750,369.42 shares12.6%
FMR LLC holds 12,719,555 shares with sole voting power and 12,750,369.42 shares with sole dispositive power, while Johnson is reported with sole dispositive power over the same 12,750,369.42 shares. The filers certify the shares were not acquired to change or influence control of Beam Therapeutics.
ARK Investment Management LLC and Catherine D. Wood report a significant passive stake in Beam Therapeutics Inc. common stock. As of 12/31/2025, they beneficially owned 12,467,189 shares, representing 12.29% of Beam’s common stock.
ARK has sole voting power over 11,797,335 shares and shared voting power over 232,371 shares, with sole dispositive power over all 12,467,189 shares. Catherine Wood shares voting power over 12,029,706 shares and shares dispositive power over 12,467,189 shares. They certify the position is held in the ordinary course of business without the purpose of changing or influencing control, and note that ARK Innovation ETF is the only ARK client with an interest above 5%.
Beam Therapeutics Inc. granted a stock option to senior executive Bethany J. Cavanagh, SVP, Finance and Treasurer. On 01/31/2026, she received a stock option to buy 40,000 shares of Common Stock at an exercise price of $27.62 per share, expiring 01/31/2036.
The option was awarded for no cash consideration and is held directly. It vests in equal monthly installments over the 48 months following the grant date, conditioned on her continued service with Beam Therapeutics Inc. through each vesting date.
Beam Therapeutics Inc. reported an insider equity award for its President, Giuseppe Ciaramella. On January 31, 2026, he received a stock option to buy 80,000 shares of common stock at an exercise price of $27.62 per share.
The option was granted directly to him and is scheduled to vest in equal monthly installments over 48 months following the grant date. Each vesting installment is conditioned on his continued service with Beam Therapeutics through the applicable vesting date.